Gene therapy in bladder cancer

Current Opinion in Urology

Volumn 18, Issue 5, 2008, Pages 519-523

  Bochner, Bernard H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder cancer; Gene therapy; Virus

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CYTOSINE DEAMINASE; ETOPOSIDE; FLUCYTOSINE; FLUDARABINE; VALPROIC ACID;

BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; BLADDER TUMOR; GENE THERAPY;

GENE THERAPY; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 54549099158     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32830b86e3     Document Type: Review

References (47)

1. Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59:325-330.
2. Loskog A, Hedlund T, Wester K, et al. Human urinary bladder carcinomas express adenovirus attachment and internalization receptors. Gene Ther 2002; 9:547-553.
3. Buscarini M, Quek ML, Gilliam-Hegarich S, et al. Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. Urol Int 2007; 78:160-166.
4. Sabichi A, Keyhani A, Tanaka N, et al. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol 2006; 175:1133-1137.
5. Sachs MD, Ramamurthy M, Poel H, et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 2004; 11:477-486.
6. Segura-Pacheco B, Avalos B, Rangel E, et al. HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo. Genet Vaccines Ther 2007; 5:10.
7. Yamashita M, Rosser CJ, Zhou JH, et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther 2002; 9:687-691.
8. Benedict WF, Tao Z, Kim CS, et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 2004; 10:525-532.
9. Connor RJ, Anderson JM, Machemer T, et al. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 2005; 66:224-229.
10. Tao Z, Connor RJ, Ashoori F, et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther 2006; 13:125-130.
11. Nagabhushan TL, Maneval DC, Benedict WF, et al. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. Cytokine Growth Factor Rev 2007; 18:389-394.
12. Shichinohe T, Bochner BH, Mizutani K, et al. Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther 2001; 8:879-889.
13. Li S, Rosenberg JE, Donjacour AA, et al. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and antitelomerase short-interfering RNA. Cancer Res 2004; 64:4833-4840.
14. Kikuchi E, Menendez S, Ozu C, et al. Highly efficient gene delivery for bladder cancers by intravesically administered replication- competent retroviral vectors. Clin Cancer Res 2007; 13:4511-4518.
15. Kikuchi E, Menendez S, Ozu C, et al. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther 2007; 14:279-286.
16. Shiau AL, Lin YP, Shieh GS, et al. Development of a conditionally replicating pseudorabies virus for HER-2/neu-overexpressing bladder cancer therapy. Mol Ther 2007; 15:131-138.
17. Terao S, Shirakawa T, Kubo S, et al. Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model. Urology 2007; 70:1009-1013.
18. Melquist JJ, Kacka M, Li Y, et al. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model. Urol Oncol 2006; 24:362-371.
19. van der Poel HG, Molenaar B, van Beusechem VW, et al. Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer. J Urol 2002; 168:266-272.
20. Pan CX, Koeneman KS. A novel tumor-specific gene therapy for bladder cancer. Med Hypotheses 1999; 53:130-135.
21. Inoue M, Tomizawa K, Matsushita M, et al. p53 protein transduction therapy: successful targeting and inhibition of the growth of the bladder cancer cells. Eur Urol 2006; 49:161-168.
22. McGarvey TW, Meng RD, Johnson O, et al. Growth inhibitory effect of p21 and p53 containing adenoviruses on transitional cell carcinoma cell lines in vitro and in vivo. Urol Oncol 2001; 6:155-162.
23. Werthman PE, Drazan KE, Rosenthal JT, et al. Adenoviral-p53 gene transfer to orthotopic and peritoneal murinebladder cancer.J Urol 1996; 155:753-756.
24. Miyake H, Hara I, Gohji K, et al. Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer. Anticancer Res 1998; 18:3087-3092.
25. Miyake H, Hara I, Hara S, et al. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated p53 gene transfer in human bladder cancer model. Urology 2000; 56:332-336.
26. Perrotte P, Wood M, Slaton JW, et al. Biosafety of in vivo adenovirus-p53 intravesical administration in mice. Urology 2000; 56:155-159.
27. Irie A, Uchida T, Ishida H, et al. p53 mutation in bladder cancer patients in Japan and inhibition of growth by in vitro adenovirus-mediated wild-type p53 transduction in bladder cancer cells. Mol Urol 2001; 5:53-58.
28. Shirakawa T, Sasaki R, Gardner TA, et al. Drug-resistant human bladdercancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells. Int J Cancer 2001; 94: 282-289.
29. Wada Y, Gotoh A, Shirakawa T, et al. Gene therapy for bladder cancer using adenoviral vector. Mol Urol 2001; 5:47-52.
30. Kuball J, Wen SF, Leissner J, et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002; 20:957-965.
31. Pagliaro LC, Keyhani A, Liu B, et al. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol 2003; 21:456-462.
32. Pagliaro LC, Keyhani A, Williams D, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 2003; 21:2247-2253.
33. Fodor I, Timiryasova T, Denes B, et al. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 2005; 173:604-609.
34. Miyake H, Yamanaka K, Muramaki M, et al. Therapeutic efficacy of adenoviralmediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia 2005; 7:171-179.
35. Irie A, Matsumoto K, Anderegg B, et al. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and antierbB2 ribozyme, against human bladder cancer cells. Cancer Gene Ther 2006; 13:298-305.
36. Ruifa H, Liwei L, Binxin L, et al. Additional gene therapy with rAAV-wt-p53 enhanced the efficacy of cisplatin in human bladder cancer cells. Urol Int 2006; 77:355-361.
37. Matsumoto K, Freund CT, Teh BS, et al. Novel therapeutic approach for bladder cancer: synergistic effects with combined radiation and suicide gene therapy using a chimeric adenovirus vector. Int J Radiat Oncol Biol Phys 2004; 60:S376-S377.
38. Zhang Z, Shirakawa T, Hinata N, et al. Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation. J Gene Med 2003; 5:860-867.
39. Shieh GS, Shiau AL, Yo YT, et al. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res 2006; 66:9957-9966.
40. Sutton MA, Berkman SA, Chen SH, et al. Adenovirus-mediated suicide gene therapy for experimental bladder cancer. Urology 1997; 49:173-180.
41. Freund CT, Sutton MA, Dang T, et al. Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. Anticancer Res 2000; 20:1359-1365.
42. Freund CT, Tong XW, Block A, et al. Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus-and Rous sarcoma virus-promoter. Anticancer Res 2000; 20:2811-2816.
43. Sutton MA, Freund CT, Berkman SA, et al. In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. Mol Ther 2000; 2:211-217.
44. Akasaka S, Suzuki S, Shimizu H, et al. Suicide gene therapy for chemically induced rat bladder tumor entailing instillation of adenoviral vectors. Jpn J Cancer Res 2001; 92:568-575.
45. Cheon J,Moon DG, Cho HY,et al. Adenovirus-mediated suicide-gene therapy in an orthotopic murine bladder tumor model. Int J Urol 2002; 9:261-267.
46. Freytag SO, Paielli D, Wing M, et al. Efficacy and toxicity of replicationcompetent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 2002; 54:873-885.
47. Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapycounteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 2005; 11:8816-8821.